Lancet 366(9491):10591062
Limitations and future directions As with any animal study, the limitation of the current study is the application of its findings to human settings, which is challenging due to both obvious and subtle distinctions between humans and animals
25 Given concerns that skeletal muscle loss may predispose patients to long-term metabolic complications, including sarcopenia, it is recommended that individuals undergoing treatment with GLP-1 RAs receive adequate protein intake and appropriate micronutrient supplementation to preserve muscle mass and function, thereby maximizing the clinical benefits of therapy
Total peptide needed by protocol length Now translate those totals into vials
Schmidt DA, Held K, Ising M, Uhr M, Weikel JC, Steiger A
Choose between an in-clinic visit or a convenient phone consultation whichever works best for you